5,6-二氢苯并[d]噻唑-7(4H)-酮 | 935850-03-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5,6-二氢苯并[d]噻唑-7(4H)-酮
• 中文别名: 5,6-二氢苯并[D]噻唑-7(4H)-酮
• 英文名称: 4,5,6,7-tetrahydrobenzothiazol-7-one
• 英文别名: 5,6-dihydro-1,3-benzothiazol-7(4H)-one；5,6-Dihydrobenzo[D]thiazol-7(4H)-one；5,6-dihydro-4H-1,3-benzothiazol-7-one
• CAS: 935850-03-6
• 化学式: C₇H₇NOS
• 分子量: 153.205
• InChiKey: RENBIQXXBKOXQC-UHFFFAOYSA-N

物化性质

• 沸点：
  298.3±9.0 °C(Predicted)
• 密度：
  1.326±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934200090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5,6-二氢苯并[d]噻唑-7(4H)-酮 在 氢溴酸 、 溴 、 溶剂黄146 作用下， 反应 8.5h， 以77%的产率得到6,6-dibromo-5,6-dihydro-1,3-benzothiazol-7(4H)-one
  参考文献：
  名称：

  Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1<i>H</i>-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia

  摘要：

  合成7-甲氧基-6-[4-(4-甲基-1,3-噻唑-2-基)-1H-咪唑-5-基]-1,3-苯并噻唑11 (TASP0382088)并评价其转化生长β 因子 (TGF-β) I 型受体（也称为激活素受体样激酶 5 或 ALK5）抑制剂。化合物 11 是一种有效的选择性 ALK5 抑制剂，具有良好的酶抑制活性 (IC50=4.8 nM) 以及细胞水平上对 TGF-β 诱导的 Smad2/3 磷酸化的抑制活性 (IC50 =17 n<小>M）。在1的苯并噻唑环上引入甲氧基以及咪唑环和噻唑环之间平面性的破坏提高了11在洗剂基质中的溶解度。此外，局部应用3％11洗剂显着抑制Smad2应用后 8 小时，小鼠皮肤发生磷酸化（与媒介物处理的动物相比，抑制率为 71%）。

  DOI：

  10.1248/cpb.c12-00856
• 作为产物：
  描述：

  2-氯-5,6-二氢-4H-苯并噻唑-7-酮 在 铁粉 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 以82%的产率得到5,6-二氢苯并[d]噻唑-7(4H)-酮
  参考文献：
  名称：

  Synthesis of 8-piperidino-5,6-dihydro-4H-thiazolo[5,4-c]azepines and 8-amino-5,6-dihydro-4H-bis[1,3]thiazolo-[3,2-a: 5′,4′-c]azepin-7-ium chlorides

  摘要：

  DOI：

  10.1134/s1070363206070334

文献信息

• [EN] 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS<br/>[FR] 2-AMINOPHENYL-4-PHENYLPYRIMIDINES UTILISEES COMME INHIBITEURS DE KINASES
  申请人：CYCLACEL LTD

  公开号：WO2005012262A1

  公开（公告）日：2005-02-10

  The present invention relates to compounds of Formula: (I), or pharmaceutically acceptable salt thereof, wherein the variables are defined in the description. The compounds act as kinase inhibitors.

  本发明涉及式(I)的化合物或其药用可接受的盐，其中变量在描述中有定义。这些化合物作为激酶抑制剂。
• Substituted oxoazaheterocyclyl compounds
  申请人：AVENTIS PHARMACEUTICALS INC.

  公开号：US20040102450A1

  公开（公告）日：2004-05-27

  This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..

  这项发明涉及抑制因子Xa的氧杂杂环化合物，抑制同时抑制因子Xa和因子IIa的氧杂杂环化合物，包含这些化合物的药物组合物，用于制备这些化合物的中间体，直接抑制因子Xa的方法，以及同时直接抑制因子Xa和因子IIa的方法。
• [EN] THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROT EIN KINASES<br/>[FR] COMPOSES A BASE DE THIAZOLO-, OXAZALO ET IMIDAZOLO-QUINAZOLINE CAPABLES D'INHIBITION DE PROTEINE-KINASES
  申请人：CYCLACEL LTD

  公开号：WO2005005438A1

  公开（公告）日：2005-01-20

  compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: X is S, 0, or NH; 'a' is a single bond; or 'a' is a double bond and one of R3 and R4 and one of R5 and R6 are absent; R1 is H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, S02-alkyl, C02R13 and an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from R8 and R9; R2 is H, R8 , or an alkyl group optionally substituted with one or more R8 groups; R3 , R4, R5, and R6 are each independently selected from H, R8 , an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more R8 groups; or R3 and R4, and/or R5 and R6 together represent =0; R7 is H, R8, NH(CH2)nR9, CO(CH2)nR9, NHCO(CH2)nR9, O(CH2)nR9, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from R8 and R9; R8 is OR10, NR10R11, halogen, CF3, N02, COR10, CN, COOR10, CONR10R11, S02R10 or S02NR10R11; R9 is a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, 0 and S, and optionally substituted with one or more R8 groups; R10, R11, R12 and R13 are each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula (1), and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.

  化合物的公式（1）或其药学上可接受的盐，其中：X为S、O或NH；'a'为单键；或'a'为双键，且R3和R4中的一个以及R5和R6中的一个不存在；R1为H；或从烷基、环烷基、杂环烷基、芳基、CO-烷基、SO2-烷基、CO2R13和芳基中选择，每种基可选地含有一个或多个杂原子，并可选地用R8和R9中的一个或多个基替代；R2为H、R8或烷基，烷基可选地用一个或多个R8基替代；R3、R4、R5和R6各自独立地选自H、R8、烷基和烯基，其中所述烷基和烯基可选地用一个或多个R8基替代；或R3和R4，和/或R5和R6一起代表=O；R7为H、R8、NH(CH2)nR9、CO( )nR9、NHCO( )nR9、O( )nR9或烷基或苯基，每种基可选地用一个或多个R8和R9中的一个或多个基替代；R8为OR10、NR10R11、卤素、CF3、NO2、COR10、CN、COOR10、CONR10R11、SO2R10或SO2NR10R11；R9为饱和或不饱和的含有一个或多个来自N、O和S的杂原子的5-或6-成员环基，并可选地用一个或多个R8基替代；R10、R11、R12和R13各自独立地为H或烃基；n为0、1、2或3。该发明的进一步方面涉及包含化合物的公式（1）的药物组合物，以及其在治疗增殖性疾病、病毒性疾病、中枢神经系统疾病、糖尿病、中风和心血管疾病中的治疗用途。
• [EN] THIAZOLYL-DIHYDRO-INDAZOLES<br/>[FR] THIAZOLYLDIHYDROINDAZOLES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009112565A1

  公开（公告）日：2009-09-17

  The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中R1至R3的化合物，其中R1至R3的定义如权利要求书中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。
• [EN] PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY<br/>[FR] COMPOSES DE PYRIMIDIN-4-YL-3, 4-THIONE ET LEUR UTILISATION A DES FINS THERAPEUTIQUES
  申请人：CYCLACEL LTD

  公开号：WO2005042525A1

  公开（公告）日：2005-05-12

  The present invention relates to compounds of formula: (I), or pharmaceutically acceptable salts thereof, wherein R1 and R5 are each independently H, C(ORj’) or a hydrocarbyl group optionally substituted by one or more R6 groups; R2, R3, and R4 are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7 groups; R6 and R7 are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa’CORg’, Rf’, (CH2)rNRb’SO2Rh’, SO2NRd’Ri’, SO2NRe'(CH2)s,ORc', heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rm and CORn; Rg', Rh', Ri' and Rj' are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2 CF3 and COOH; m, p, q and r are each independently 0, 1, 2 or 3; n and s are each independently 1, 2, or 3; and Ra-n and Ra'-f' are each independently H or alkyl. Further aspects of the invention relate to pharmaceutical compositions comprising such compounds, and their use in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a CNS disorder, a stroke, alopecia and diabetes.

  本发明涉及以下结构的化合物：(I)，或其药学上可接受的盐，其中R1和R5分别独立地为H、C(ORj’)或一个或多个R6基团取代的烃基团；R2、R3和R4分别独立地为H、烷基或烯基，每个基团可能选择性地用一个或多个R7基团取代；R6和R7分别独立地为卤素、NO2、CN、(CH2)mORa、O( )nORb、( )pNRcRd、CF3、COORe、CONRfRg、CORh、SO3H、SO2Ri、SO2NRjRk、( )qNRa’CORg’、Rf’、( )rNRb’SO2Rh’、SO2NRd’Ri’、SO2NRe'( )s、ORc'、杂环烷基或杂芳基，其中所述的杂环烷基和杂芳基可以选择性地用一个或多个从芳基烷基、磺酰基、Rm和CORn中选择的取代基团取代；Rg'、Rh'、Ri'和Rj'分别独立地选择自烷基、芳基、芳基烷基和杂芳基，每个基团可能选择性地用一个或多个从卤素、OH、 、NH2、 和COOH中选择的取代基团取代；m、p、q和r分别独立地为0、1、2或3；n和s分别独立地为1、2或3；以及Ra-n和Ra'-f'分别独立地为H或烷基。本发明的进一步方面涉及包含这种化合物的药物组合物，以及它们在制备治疗以下一种或多种疾病的药物中的用途：增生性疾病、病毒性疾病、中枢神经系统疾病、中风、脱发和糖尿病。